Pakistan Production Of Generics Slows To Near Halt Over Price Issues
This article was originally published in PharmAsia News
Pakistan production of generic drugs has ground nearly to a halt on the Drug Regulatory Authority's long-delayed decision on revising the price controls.
You may also be interested in...
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.